Strategic Blueprint
VRTX icon

Strategic Blueprint’s Vertex Pharmaceuticals VRTX Stock Holding History

Strategic Blueprint’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$356K Sell
680
-115
-14% -$58.9K 0.02% 522
2026
Q2 		$395K Buy
795
+74
+10% +$32.8K 0.02% 510
2026
Q1 		$322K Buy
721
+121
+20% +$56.4K 0.02% 504
2025
Q4 		$272K Sell
600
-1,164
-66% -$502K 0.02% 544
2025
Q3 		$691K Sell
1,764
-43
-2% -$18K 0.03% 412
2025
Q2 		$804K Buy
1,807
+309
+21% +$142K 0.04% 345
2025
Q1 		$726K Buy
1,498
+25
+2% +$11.6K 0.04% 345
2024
Q4 		$593K Buy
1,473
+386
+36% +$179K 0.04% 372
2024
Q3 		$506K Buy
1,087
+7
+0.6% +$3.36K 0.03% 396
2024
Q2 		$506K Buy
1,080
+120
+13% +$52.1K 0.03% 377
2024
Q1 		$401K Buy
960
+304
+46% +$129K 0.03% 427
2023
Q4 		$267K Buy
+656
New +$242K 0.02% 486
2021
Q3 		– Sell
-59
Closed -$12K – 1305
2021
Q2 		$12K Buy
+59
New +$12.3K ﹤0.01% 937
2020
Q4 		– Sell
-1,278
Closed -$348K – 265
2020
Q3 		$348K Buy
+1,278
New +$353K 0.11% 155

Other funds holding VRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $59.1B AUM 41.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Strategic Blueprint's VRTX Position: Q3 2026 in Review

Strategic Blueprint reduced its Vertex Pharmaceuticals (VRTX) stake by 14% in Q3 2026, selling an estimated $58.9K and leaving 680 shares worth $356K. The position accounts for 0.02% of the portfolio, ranked #522.

Strategic Blueprint first reported a position in VRTX in Q3 2020 and has held it in 14 quarters since. The position peaked at $804K in Q2 2025. 1,161 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Strategic Blueprint held 680 shares of Vertex Pharmaceuticals worth $356K as of Q3 2026.
  • Strategic Blueprint sold 115 Vertex Pharmaceuticals shares in Q3 2026, an estimated $58.9K.
  • Vertex Pharmaceuticals made up 0.02% of Strategic Blueprint's portfolio in Q3 2026, its #522 holding.
  • Strategic Blueprint first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 14 quarters since.
  • Strategic Blueprint's Vertex Pharmaceuticals position peaked at $804K in Q2 2025.
  • 1,161 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Strategic Blueprint's 13F filing for Q3 2026, filed 22 Oct 2026.